Integer Holdings Corporation $ITGR Shares Sold by Fuller & Thaler Asset Management Inc.

Key Points

• Fuller & Thaler Asset Management Inc. reduced its holdings in Integer Holdings Corporation by 18.7%, now owning approximately 2.28% of the company, valued at $93,732,000.
• Recent analyst reports reflect mixed sentiments for Integer, with price targets adjusted down by firms like Raymond James and Truist Financial, while others like Citigroup upgraded the stock to a "strong-buy".
• Integer reported a quarterly revenue of $476 million, surpassing analysts' expectations, but reported an EPS of $1.55, missing consensus estimates by $0.02.

Fuller & Thaler Asset Management Inc. reduced its position in shares of Integer Holdings Corporation (NYSE:ITGR - Free Report) by 18.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 794,274 shares of the medical equipment provider's stock after selling 182,898 shares during the period. Fuller & Thaler Asset Management Inc. owned about 2.28% of Integer worth $93,732,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ITGR. AdvisorNet Financial Inc bought a new position in Integer in the 1st quarter valued at approximately $28,000. Opal Wealth Advisors LLC purchased a new position in Integer in the first quarter valued at approximately $28,000. Bessemer Group Inc. boosted its holdings in shares of Integer by 73.1% in the first quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider's stock worth $35,000 after acquiring an additional 125 shares during the period. Sterling Capital Management LLC increased its stake in Integer by 472.9% in the fourth quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider's stock valued at $45,000 after acquiring an additional 279 shares during the last quarter. Finally, Headlands Technologies LLC boosted its holdings in Integer by 1,234.8% during the 1st quarter. Headlands Technologies LLC now owns 1,228 shares of the medical equipment provider's stock valued at $145,000 after acquiring an additional 1,136 shares during the period. Institutional investors own 99.29% of the company's stock.

Integer Stock Performance

Shares of Integer stock traded up $3.8190 on Friday, hitting $110.6490. The stock had a trading volume of 256,433 shares, compared to its average volume of 373,536. Integer Holdings Corporation has a 52-week low of $104.93 and a 52-week high of $146.36. The company has a current ratio of 3.41, a quick ratio of 2.18 and a debt-to-equity ratio of 0.72. The stock has a market cap of $3.88 billion, a price-to-earnings ratio of 48.74, a P/E/G ratio of 0.84 and a beta of 1.02. The company's 50 day moving average price is $113.76 and its 200 day moving average price is $119.20.

Integer (NYSE:ITGR - Get Free Report) last announced its earnings results on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.02). The company had revenue of $476.00 million during the quarter, compared to analysts' expectations of $464.37 million. Integer had a net margin of 4.61% and a return on equity of 12.27%. The company's revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.30 earnings per share. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. On average, research analysts anticipate that Integer Holdings Corporation will post 6.01 EPS for the current year.

Insiders Place Their Bets

In other news, Director Martin C. Maxwell sold 8,720 shares of Integer stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $120.56, for a total transaction of $1,051,283.20. Following the sale, the director directly owned 22,170 shares of the company's stock, valued at approximately $2,672,815.20. The trade was a 28.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Donald J. Spence sold 14,739 shares of Integer stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $120.38, for a total value of $1,774,280.82. Following the sale, the director directly owned 18,781 shares in the company, valued at approximately $2,260,856.78. The trade was a 43.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ITGR. Truist Financial dropped their price target on Integer from $145.00 to $137.00 and set a "buy" rating on the stock in a research report on Friday, July 25th. Benchmark decreased their price objective on shares of Integer from $150.00 to $140.00 and set a "buy" rating for the company in a research note on Friday, April 25th. Raymond James Financial reduced their price target on Integer from $150.00 to $143.00 and set an "outperform" rating for the company in a research report on Friday, July 25th. Wall Street Zen raised Integer from a "sell" rating to a "hold" rating in a research report on Monday, May 19th. Finally, Wells Fargo & Company cut their price target on Integer from $152.00 to $132.00 and set an "overweight" rating on the stock in a research report on Friday, July 25th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $140.25.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.